in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pfizer eyes AstraZeneca for a reported $100 billion
8:26 AM MDT | April 22, 2014 | Natasha Alperowicz
UK press over the weekend said that Pfizer has made initial approaches to acquire AstraZeneca for £60 billion ($101 billion) in the world’s largest pharma acquisition. Both companies declined to comment on the report, which appears in The Sunday Times. A deal between Pfizer and AstraZeneca would create one of the top 10 companies globally by market value. AstraZeneca has rejected Pfizer’s overtures, according to the reports. AstraZeneca is in a transitional phase, with sales and earnings expected to decline for the next couple of years...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee